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ascribed to smoking cessation. Seven new warnings were introduced on 
tobacco products in Australia in March 2006 and a second set intro-
duced in November 2006 including graphic images of health effects 
such as peripheral vascular disease, mouth and throat cancer, lung can-
cer and stroke. A $10M AUD campaign strategy was developed in New 
South Wales (NSW). It included a mass media campaign designed to 
increase the likelihood of smokers making a successful quit attempt by:
a) adding depth, meaning and personal relevance to the new pictorial 
health warnings and 
b) maintaining the impact of the warnings far beyond the anticipated 
newsworthiness of their initial introduction.
The health warnings campaign was launched in May 2006 and focused 
on the graphic images of peripheral vascular disease (amputation) and 
mouth and throat cancer. The campaign was supported by complemen-
tary research driven media messages about smoker’s self exempting 
beliefs and the health consequences of their excuses. In addition, to 
maximise the chance of the intended behavioural response smokers 
need accessible and reliable services to help them quit. A Quitline 
services campaign was also run to promote the smokers’ help-line that 
focused on support for smokers on topics such as planning a quit at-
tempt, nicotine replacement therapy and cravings.
Calls to the Quitline (smokers’ help-line) more than doubled from 
27,000 in 2005, to 57,000 in 2006, increasing to an average monthly 
call rate of 5,000 and peaking at 9,400 in the month of May 2006. 
Campaign tracking research showed a high awareness of the “amputa-
tion” and “mouth cancer” advertising and the graphic warnings on 
packs. Call response was closely associated media weight and to recall 
of the graphic warnings campaign. In the year 2006, smoking preva-
lence in NSW adults (aged 16 years and over) showed the largest drop 
ever recorded the previous average decline was 0.5% per year over 
ten years. Smoking prevalence has declined from 20.1% in 2005 to 
17.7% overall in 2006 (daily and occasional smoking). The decline was 
greater among males with 15% of males reporting daily smoking (down 
2.5%) and 12.9% of females reporting daily smoking (down 1.2%). 
In NSW this fall represents around 76,800 smokers (age-adjusted) 
who have reported quitting in 12 months. In addition, smoking rates 
amongst teenagers were at the lowest rate in 20 years indicating social 
norms around smoking are shifting. Graphic warnings on tobacco 
products, supported by well-funded mass media campaigns and an ap-
propriate legislative framework, have led to dramatic falls in smoking 
prevalence in NSW.
C8-07 Epidemiology & Tobacco Control, Wed, 10:30 - 12:15
The National Lung Cancer Audit (LUCADA) programme in  
England 
Peake, Michael D.1 Chanarin, Nicholas1 Stanley, Rosamund A.2 
1 Clinical Effectiveness and Evaluation Unit, Royal College of Physi-
cians, London, UK 2 National Information Centre, Leeds, UK 
Survival rates for lung cancer patients in the UK are below those of 
most western countries. and there is a four-fold difference in the 5yr 
survival rate between the best and worst performing areas of the coun-
try. We do not understand the reasons for these differences and how 
best to correct them. The National Lung Cancer audit (LUng CAncer 
DAta) programme for England (and Wales) has been established to 
provide the mechanism for the ongoing collection and analysis of data 
to try and answer some of these questions and to steer service improve-
ment. The programme is currently commissioned by the Healthcare 
Commission and managed within the Information Centre for Health 
and Social Care in partnership with the Royal College of Physicians. 
LUCADA began collecting data in 2004 (with 2005 being the ﬁrst full 
year) and as at 28.2.07 had 35,027 patient records on the database. We 
estimate that for 2006 this will include nearly 60% of the incident cases 
in England. The ﬁrst annual report was published in December 2006 
and contained data on all cases of lung cancer with an initial date of 
referral in 2005. This abstract describes some data from that popula-
tion, but by in September 2007 we will be in a position to report to 
the World Lung Cancer Conference on the 2006 data. By the end of 
February 2007 >90% of the eligible hospitals from all 34 of the English 
Cancer Networks had submitted data. For the 10,920 cases of lung 
cancer diagnosed in 2005 the median age was 72 (range 18-101): 6584 
males and 4336 females. Only 57% of these cases had a conﬁrmed 
tissue diagnosis (interquartile range by cancer network: 48%-73%; 
median 63%). 78% of patients were reviewed by a multi-disciplinary 
team (interquartile range: 70%-92%; median 82%). 8.6% underwent 
surgical resection (interquartile range: 4.4%-10.8%; median 6.9%) and 
only 43% of patients received any active-cancer treatment (interquartile 
range: 35%-63%; median 48%). These values are low by international 
standards and demonstrate signiﬁcant regional variation across Eng-
land. Incomplete data collection can probably, at least in part, explain 
these apparently low rates. By collecting data on case-mix variables 
such as postcode (and therefore deprivation status), age, cell type, 
performance status, co-morbidity and stage at presentation, the Na-
tional Lung Cancer Audit programme intends to carry out risk-adjusted 
analyses which, it is hoped, will start to explain some of the variations 
in practice and outcomes. The data from 2005 was not of a sufﬁciently 
high standard of completeness to allow for this, but we are hopeful that 
this will be possible on 2006 data from at least a proportion of centres.
The National Lung Cancer Audit continues to recruit steadily and is 
now, we believe, the largest audit of lung cancer services ever attempt-
ed. The continuing aim is to encourage participation with comprehen-
sive data collection so that risk adjusted comparative data on activity, 
performance and outcomes becomes regularly available with the aim of 
improving patient outcomes for the future. 
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Background: Cytologic approaches such as pleural lavage cytology 
(PLC) are considered as aids to assessing prognosis of lung cancers. 
However, there is some controversy whether radical surgery is war-
ranted based on the positive PLC ﬁndings with early-stage non-small 
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cell lung cancers (NSCLCs). The present study, a prospective trial 
built on our experience with PLC in patients undergoing resection for 
NSCLCs and followed for long-term outcome, was undertaken to ana-
lyze survival and pattern of recurrence with particular reference to PLC 
ﬁndings with early stage diseases.
Methods: From January 1991 to December 2003, PLC was performed 
before any manipulation or resection of the lung for 915 consecutive 
patients who had no macroscopic pleural effusion, dissemination or 
diffuse adhesions and who subsequently underwent curative resection 
for NSCLCs. Results of PLC with reference to clinical and pathologic 
characteristics (gender, age, tumor location, histology, postoperative 
stage, T category, N category and p status), adjuvant therapy, 5-year 
survival and recurrence patterns were analyzed. Cancer recurrence was 
divided into three categories according to the sites of initial recurrence: 
loco-regional, pleural and distant. Pleural recurrence was deﬁned as 
any recurrent disease within the hemithoracic pleura.
Results: There were 367 women and 548 men, with a mean age of 
62.8 years (range, 16 to 86 years). The ﬁndings of cytologic examina-
tion were not inﬂuenced by age (P=0.80). Among the total, 43 (4.7%) 
had positive PLC ﬁndings: 26(4.7%) males and 17 (4.6%) females. 
Positive results were obtained much more frequently in patients with 
adenosquamous carcinoma (13%) or adenocarcinomas (5.6%) and 
were lacking with squamous cell carcinomas and large cell carcinomas. 
The overall 5-year survival rate was 41% in patients with positive 
PLC ﬁndings and 74% in patients with negative results, the difference 
being statistically signiﬁcant (P=0.001). The 5-year survival rates of 
patients with stage I disease with negative and positive cytologic ﬁnd-
ings were 85% and 56% respectively, again with statistical signiﬁcance 
(P=0.001). In the positive PLC group, distant metastases (69%) and 
pleural recurrence (28%; P<0.0001) were often observed, even for 
patients with stage I diseases (P<0.001). As adjuvant therapies in 
the positive group, six patients had hypotonic cisplatin and 18 had 
distilled water infusion into the pleural space after lung resection. The 
5-year survival rates for the two positive PLC groups with and without 
adjuvant therapy were 38% and 45% respectively, the difference be-
ing statistically not signiﬁcant (P=0.16). Although only three patients 
suffered from pleural recurrence, these therapies did not improve long-
term outcome. 
Conclusions: Although the numbers of patients with positive PLC 
results were limited, as in many other studies on this topic, our 
results conﬁrm that PLC is a distinct prognostic factor for early-stage 
NSCLCs. Thus, we suggest that cytologic examination of intra-opera-
tive PLC should be performed routinely even for patients with stage I 
NSCLCs before beginning lung resection. Moreover, curative resection 
followed by any adjuvant systemic therapies could be necessary for 
improvement of outcome for PLC positive patients.
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Background: To summarize the results of extended resection of the 
heart, great vessels, or both in the treatment of 349 patients with locally 
advanced lung cancer. 
Methods: From February 1983 to December 2004, lobectomy or 
pneumonectomy combined with extended resection of the heart, great 
cessels or both were carried out in 1049 patients with locally advanced 
lung cancer. The operations included bronchoplastic procedures and 
pulmonary artery reconstruction in 725 cases, extended resection of left 
atrium in 145 cases, superior vena cava resection and reconstruction in 
175 cases (21 patients had carina resection and reconstruction simulta-
neously), and aorta resection and reconstruction in 4 cases respectively. 
Results: There were 10 operative death. The operative mortality was 
0.95% in the series. Ninty-three patients had operative complications. 
The 1,3,5 and 10-year survival rates were 74.36%, 51.93%,32.14% and 
22.56% respectively. 
Conclusion: Selectively extended resection of the heart, great vessels 
or both can remarkably increase the long-term survival and improve the 
prognosis in patient with locally advanced non-small cell lung cancer. 
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Background: QOL is a multidimensional phenomenon that can be 
inﬂuenced by the experience of living with lung cancer. Disruptions 
in QOL are important to monitor during the entire continuum of the 
disease, from diagnosis to treatment, during recovery and rehabilita-
tion. Although QOL data frequently are obtained in clinical trials for 
advanced lung cancer, information is limited about QOL after the initial 
diagnosis and treatment when individuals continue to live and are faced 
with the possibility of recurrence and metastasis. Furthermore it is 
unknown if QOL can be inﬂuenced by follow-up and rehabilitation.
Material: 145 patients (86 men, 59 women) were included in this study 
after radical surgery for non-small cell lung cancer. Type of resection 
included lobectomy (n=99), pneumonectomy (n=32) and segment/sub-
segment resection (n=14). The remaining patients were referred to 
oncological treatment and excluded from the study. Only patients who re-
sponded to the preoperative and at least one postoperative Quality of Life 
questionnaire EORTC QLQ-C30 are included in this preliminary report.
Methods: All patients underwent standard surgical resection with a 
posterolateral thoracotomy. Adjuvant chemotherapy was offered to all 
stages except 1a. After radical surgery, patients were offered participa-
tion in the study and randomized to either intensive follow-up and reha-
